Chat with us in Facebook Messenger. Find out what's happening in the world as it unfolds.

FILE -  In this May 6, 2010 file photo, detection lead mammographer, Toborcia Bedgood, left, prepares a screen-film mammography test for patient Alicia Maldonado, at The Elizabeth Center for Cancer Detection in Los Angeles. A new, international panel of experts has studied the most recent evidence on mammograms to screen for breast cancer and says they do the most good for women in their 50s and 60s. Women 70 to 74 also benefit to a lesser extent. But evidence that screening helps women in their 40s is "limited," the panel said, although some members disagreed this was true for women 45 to 49. (AP Photo/Damian Dovarganes, File)
FILE -  In this May 6, 2010 file photo, detection lead mammographer, Toborcia Bedgood, left, prepares a screen-film mammography test for patient Alicia Maldonado, at The Elizabeth Center for Cancer Detection in Los Angeles. A new, international panel of experts has studied the most recent evidence on mammograms to screen for breast cancer and says they do the most good for women in their 50s and 60s. Women 70 to 74 also benefit to a lesser extent. But evidence that screening helps women in their 40s is "limited," the panel said, although some members disagreed this was true for women 45 to 49. (AP Photo/Damian Dovarganes, File)

    JUST WATCHED

    Este es el último y revolucionario tratamiento para tratar el cáncer

MUST WATCH

Este es el último y revolucionario tratamiento para tratar el cáncer

El doctor Elmer Huerta explica que actualmente los tratamientos se dirigen solamente al órgano afectado, pero por primera vez la FDA aprobó un medicamento que no actúa en el órgano específico sino que en "marcadores genéticos que pueden ser comunes en diferentes tipos de cáncer".

Este es el último y revolucionario tratamiento para tratar el cáncer

El doctor Elmer Huerta explica que actualmente los tratamientos se dirigen solamente al órgano afectado, pero por primera vez la FDA aprobó un medicamento que no actúa en el órgano específico sino que en "marcadores genéticos que pueden ser comunes en diferentes tipos de cáncer".